144 related articles for article (PubMed ID: 17643885)
1. A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors.
Narasimha A; Watanabe J; Lin JA; Hama S; Langenbach R; Navab M; Fogelman AM; Reddy ST
Prostaglandins Other Lipid Mediat; 2007 Aug; 84(1-2):24-33. PubMed ID: 17643885
[TBL] [Abstract][Full Text] [Related]
2. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
3. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
[TBL] [Abstract][Full Text] [Related]
4. Systemic inflammation, intestine, and paraoxonase-1.
Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
[TBL] [Abstract][Full Text] [Related]
5. Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.
Choi JH; Jeon HJ; Park JG; Sonn SK; Lee MR; Lee MN; You HJ; Kim GY; Kim JH; Lee MH; Kwon OS; Nam KH; Kim HC; Jeong TS; Lee WS; Oh GT
Atherosclerosis; 2010 Sep; 212(1):146-52. PubMed ID: 20684827
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology of cyclooxygenases in cardiovascular homeostasis.
Sellers RS; Radi ZA; Khan NK
Vet Pathol; 2010 Jul; 47(4):601-13. PubMed ID: 20418470
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis.
Mackness B; Mackness M
Adv Exp Med Biol; 2010; 660():143-51. PubMed ID: 20221877
[TBL] [Abstract][Full Text] [Related]
8. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids.
Efrat M; Aviram M
Adv Exp Med Biol; 2010; 660():153-66. PubMed ID: 20221878
[TBL] [Abstract][Full Text] [Related]
9. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
[TBL] [Abstract][Full Text] [Related]
11. The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality.
Prüfer N; Kleuser B; van der Giet M
Biol Chem; 2015 Jun; 396(6-7):573-83. PubMed ID: 25252751
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
[TBL] [Abstract][Full Text] [Related]
13. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
[TBL] [Abstract][Full Text] [Related]
14. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
15. Effect of Mediterranean diet on the expression of pro-atherogenic genes in a population at high cardiovascular risk.
Llorente-Cortés V; Estruch R; Mena MP; Ros E; González MA; Fitó M; Lamuela-Raventós RM; Badimon L
Atherosclerosis; 2010 Feb; 208(2):442-50. PubMed ID: 19712933
[TBL] [Abstract][Full Text] [Related]
16. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
Mitchell JA; Warner TD
Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
[TBL] [Abstract][Full Text] [Related]
17. Lipid disorders and their relevance to outcomes in chronic kidney disease.
Vaziri ND; Norris K
Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
[TBL] [Abstract][Full Text] [Related]
19. The involvement of a cyclooxygenase 1 gene-derived protein in the antinociceptive action of paracetamol in mice.
Ayoub SS; Colville-Nash PR; Willoughby DA; Botting RM
Eur J Pharmacol; 2006 May; 538(1-3):57-65. PubMed ID: 16674937
[TBL] [Abstract][Full Text] [Related]
20. PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells.
Rival Y; Puech L; Taillandier T; Benéteau N; Rouquette A; Lestienne F; Dupont-Passelaigue E; Le Roy I; Patoiseau JF; Junquéro D
Eur J Pharmacol; 2009 Mar; 606(1-3):121-9. PubMed ID: 19374865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
